Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.29% | 84.04% | -6,507.50% | 103.23% | 54.18% |
| Total Depreciation and Amortization | -- | -- | -50.00% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20,400.00% | -100.07% | 224.50% | -422.49% | -79.84% |
| Change in Net Operating Assets | -91.54% | -64.04% | 24.64% | 134.20% | 58.26% |
| Cash from Operations | -2,525.00% | 81.40% | 31.75% | 87.86% | 34.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 609.43% | 15.22% | 130.00% | -85.29% | 70.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -86.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 626.32% | 11.76% | 126.67% | -94.72% | -71.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -313.64% | -- | -- | -- | -- |
| Net Change in Cash | -412.50% | 188.89% | 81.25% | 79.49% | -207.83% |
